Innovation: Clonal neoantigen specific tumour-infiltrating lymphocytes for cancer treatment
The issue In 2017, Achilles Therapeutics approached the MHRA to discuss quality, non-clinical, clinical and regulatory aspects of ATL001, an advanced therapy medicinal product consisting of autologous clonal neoantigen reactive T cells derived from pa… read more